Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Women were at greater risk than men for symptomatic adverse events and hematologic events.
Compared with men, women had a 34% greater likelihood of adverse events, especially if they received immunotherapy.
Clinical trials that test new cancer drugs or combinations seldom account for other medications a patient may be taking.
However, a majority of these chronic immune-related side effects were mild.
Among patients with high tumor PD-L1 expression, Libtayo lowered mortality by 43%.
Researchers reached this conclusion after reviewing data on more than 30,000 people.
Too few people seek help in easing side effects during and after cancer treatment.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.